SPOPSounding Products Oversight Panel
SPOPSingle Point of Presence
SPOPService Point of Presence
SPOPSupport Point of Presence
SPOPStandard Practices and Operating Procedures
SPOPStudent Parent Orientation Program
SPOPService Programs for Older People
SPOPSustainable Practices and Opportunities Plan
SPOPStorage Points of Presence
SPOPStreamside Property Owners Program
References in periodicals archive ?
of Gene subgroup SMGs symbol Hypermutated/ 21 PTEN microsatellite- PIK3CA unstable PIK3R1 ARID1A RPL22 KRAS ZFHX3 ARID5B CTCF CTNNB1 ATR GIGYF2 CSDE1 FGFR2 CCND1 LIMCH1 RBMX NKAP HIST1H2BD TNFAIP6 MIR1277 Copy number low/ 16 PTEN microsatellite- PIK3CA stable CTNNB1 ARID1A PIK3R1 CTCF KRAS FGFR2 CHD4 SPOP CSMD3 (b) SOX17 SGK1 BCOR MECOM METTL14 Copy number high 8 TP53 (serous-like) PIK3CA FBXW7 PPP2R1A PIK3R1 CHD4 PTEN CSMD3 (b) Molecular Gene name Somatic-mutation subgroup frequency Hypermutated/ Phosphatase and tensin homolog 87.
Mutations in SPOP constitute one major pathway, resulting to almost 15 percent of prostate cancer cases.
Christopher Barbieri, a fifth year urology resident at Weill Cornell insisted that the motivation to search for genes in this way came about because of the observation that SPOP appeared to be mutated in some cases of prostate cancer.
In addition to SPOP mutations, which occurred in 6 to 15 percent of tumours across multiple independent cohorts, investigators found mutations in the FOXA1 and MED12 genes, each of which are found in about 4 percent of patient tumors.
Further examination revealed the interesting nature of SPOP mutations.
SPOP belongs to a class of proteins named 'ubiquitin ligases', whose role is to mark other proteins in the cell for degradation.
He deployed to OEF VII with the DSTB NSC, fielding the first 12 SPOPs introduced into the theater.
As the results suggest, BPOP (columns [6] and [7], SPOP (columns [3], [4], and [5]), LFPR (columns [4], [5], and [6]), and GGDP (columns [5], [6], and [7]) are all positive.
Keener competition in this sector is captured by the significant estimates of SPOP.
Rubin and colleagues have identified a unique class of prostate cancer patients that have mutations in the gene for SPOP (Speckle-type POZ Protein).
Discovery of SPOP inhibitors will potentially create a new therapy for metastatic prostate cancer and, in time, will support highly personalized treatment for patients.